Intangible Assets

9 Months Ended

Sep. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

NOTE 4 - INTANGIBLE ASSETS

Intangible assets represent the cost of medical formulas approved for production by the National Medical Products Administration (the "NMPA", formerly China Food and Drug Administration, or CFDA). The Company did not obtain NMPA production approval for any new medical formulas during the nine months ended September 30, 2020 and 2019 and no costs were reclassified from advances to intangible assets during the nine months ended September 30, 2020 and 2019, respectively.

Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years. It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $8,893 and $8,536 for the three months ended September 30, 2020 and 2019, respectively, and $26,377 and $49,070 for the nine months ended September 30, 2020 and 2019, respectively, which was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period.

The Company evaluates each approved medical formula for impairment at the date of NMPA approval, when indications of impairment are present and also at the date of each financial statement. The Company's evaluation is based on an estimated undiscounted net cash flow model, which considers currently available market data for the related drug and the Company's estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the nine months ended September 30, 2020 and 2019.

Intangible assets consisted solely of NMPA approved medical formulas as follows:

	September 30,			December 31,
	2020			2019
Gross carrying amount	$	4,957,144		$	4,839,117
Accumulated amortization		(4,773,599	)		(4,633,506	)
Net carrying amount	$	183,545		$	205,611